Rapid PE Triage and Notification (PETN) vs AVIEW
AI Verdict
Choose Rapid PE Triage and Notification (PETN) if…
Choose Rapid PE Triage and Notification (PETN) if your primary need is the immediate, AI-powered detection of suspected central pulmonary embolisms from CTPA images. This tool is ideal for emergency departments and critical care settings requiring rapid clinician notification and workflow prioritization to accelerate acute PE patient care pathways.
View Rapid PE Triage and Notification (PETN) →Choose AVIEW if…
Choose AVIEW if your institution requires a comprehensive AI platform for the early detection, diagnosis, and long-term monitoring of multiple chronic conditions, including lung cancer, COPD, and coronary artery calcification. This solution is best suited for radiology departments and specialty clinics focused on detailed quantitative analysis, screening programs, and follow-up management across various lung and cardiac pathologies.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Rapid PE Triage and Notification (PETN) | AVIEW |
|---|---|---|
| Pricing | Contact for pricing | Subscription; one-off payment |
| Deployment | On-premise Rapid Server (dedicated or virtual) within hospital LAN/firewall, or Rapid Edge Cloud Platform. | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Rapid PE Triage and Notification (PETN)Tool A emphasizes real-time notifications to clinicians via PACS, email, and mobile app for acute conditions, suggesting a highly streamlined and immediate interaction for urgent triage. While Tool B offers comprehensive reports and 3D visualizations, Tool A's focus on rapid, multi-channel alerts for time-critical events likely translates to superior usability in its specific context of accelerating care pathways.
Clinical Value
AVIEWTool B provides comprehensive solutions for the early detection, diagnosis, and monitoring of multiple significant chronic diseases like lung cancer, COPD, and coronary artery calcification, enhancing diagnostic precision across a broader spectrum of patient needs. While Tool A offers critical value for acute pulmonary embolisms, Tool B's wider applicability to prevalent chronic conditions and screening programs offers greater overall clinical utility.
Pricing & Value
AVIEWTool B offers more transparency regarding its pricing model, specifying options like subscription or one-off payments based on installations and users. Tool A only states 'contact for pricing' and 'enterprise-level licensing,' providing less initial clarity for potential buyers to assess value. This greater detail in pricing structure gives Tool B an advantage in transparency.
Enterprise Readiness
AVIEWBoth tools are HIPAA compliant and FDA cleared, indicating readiness for regulated healthcare environments. However, Tool B offers a broader range of deployment options, including cloud-based, hybrid, locally on dedicated hardware, and locally virtualized solutions, providing greater flexibility to integrate into diverse enterprise IT infrastructures compared to Tool A's on-premise or Rapid Edge Cloud options.
Innovation
AVIEWTool B demonstrates broader AI innovation by offering a comprehensive platform for multiple diagnostic tasks and disease states within thoracic imaging, including advanced features like ILD pattern analysis and nodule matching for serial CT scans. While Tool A's rapid PE detection is innovative for acute care, Tool B's diverse application of AI across lung cancer, COPD, and coronary artery calcification shows a wider scope of advanced AI capabilities.
Support & Docs
Rapid PE Triage and Notification (PETN)RapidAI (Tool A) explicitly highlights '24/7/365 support' and a 'dedicated customer success team' with multiple international contact numbers, indicating a robust and readily available support infrastructure. Coreline Soft (Tool B) mentions 'global support' and a 'Customer Service Team' but without the same level of detail regarding availability or dedicated resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Rapid PE Triage and Notification (PETN) | AVIEW |
|---|---|---|
| Primary Focus | Rapid identification and notification of suspected central pulmonary embolisms from CTPA images. | Early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans. |
| Company | RapidAI (formerly iSchemaView) | Coreline Soft Co. |
| Key AI Detections/Analyses | Detection of suspected central pulmonary embolism (PE), CTPA image analysis, workflow triage and prioritization, real-time notifications. | Lung nodule detection and characterization, emphysema quantification, coronary artery calcium (CAC) scoring, automated segmentation, ILD pattern analysis. |
Videos
Demos, reviews, and walkthroughs featuring Rapid PE Triage and Notification (PETN) and AVIEW.